A significant proportion of patients with giant cell arteritis (GCA) remission who discontinue tocilizumab treatment after 1 year remain in clinical remission for a further 2 years. This was demonstrated in a follow-up study from the double-blind, randomised GiACTA trial . Additionally, restarting tocilizumab restores clinical remission among those patients who do experience disease flare. No new safety signals were observed.
In patients with GCA, the use of the interleukin-6 receptor inhibitor tocilizumab in combination with 26-week prednisone tapering resulted in higher rates of sustained glucocorticoid-free remission compared with placebo and prednisone tapering in week 52 of the GiACTA trial . Dr John Stone (Massachusetts General Hospital, Boston, USA) et al. aimed to investigate longer-term efficacy and safety of tocilizumab in GCA patients in this 2-year long-term extension of the GiACTA trial.
Patients in clinical remission (n=127) at t...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« How to Treat Osteoporosis Next Article
Switching among multiple infliximab biosimilars does not cause immunogenicity »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.